Daiichi Sankyo (TSE:4568) Stock Revenue Surges While Margins Stay Under Pressure

Daiichi Sankyo entered this earnings day with a stock that had drifted lower over the past week and three months, even as long term growth expectations and a discounted cash flow fair value estimate painted a more upbeat picture. The Q1 FY2027 print puts that gap in sharp focus. Total revenue reached ¥574.7b and basic earnings per share came in at ¥37.72, anchored by oncology drug sales. The key question for you now is whether a market that has marked the stock down is properly pricing the earnings power on display in this quarter.

Love the earnings resiliency from Daiichi Sankyo Company's oncology franchise but unsure whether the recent share price drift offers the right balance of quality and valuation risk? Check out 19 high quality undervalued stocks

Q1 2027 Earnings Summary

• Total Revenue (Q1 2027 vs Q1 2026): ¥574,740m vs. ¥474,597m (up 21.1%)
• Net Income Excluding Extra Items (Q1 2027 vs Q1 2026): ¥68,637m vs. ¥85,500m (down 19.7%)
• Basic EPS (Q1 2027 vs Q1 2026): ¥37.72 per share vs. ¥46.03 per share (down 18.1%)
• Trailing Twelve Month Basic EPS (Q1 2027 vs Q1 2026): ¥132.00 per share vs. ¥157.20 per share (down 16.1%)

Prefer clean charts instead of scrolling through another wall of earnings tables and figures? View Daiichi Sankyo Company's full visual breakdown, including its recent valuation picture in one place, in the company report for Daiichi Sankyo Company.

Daiichi Sankyo’s ADC Growth Story Faces Margin Reality Check

The bullish view on Daiichi Sankyo centers on ADC driven oncology leadership, backed by Enhertu and Datroway, and the idea that this will translate into stronger growth and better margins over time. Q1 supports the first half of that view. Revenue rose 21.1% to ¥574.7b, with Enhertu adding ¥64.0b year on year to reach ¥219.2b and Datroway scaling to ¥20.6b as new U.S., EU and China approvals start to flow through.

Where the thesis is less proven is on profitability and operating leverage. Core operating profit grew more slowly than revenue and net income excluding extra items fell 19.7%. Higher cost of sales, FX swollen SG&A, profit share to AstraZeneca and increased R&D spending absorbed much of the ADC upside. The oncology franchise is clearly scaling, but the milestone of meaningfully stronger margins is not yet in sight this quarter.

Compare the earnings power Daiichi Sankyo is putting up with how the stock closed at ¥2,567.5 on 31 July 2026 and see whether analysts think the oncology story still lines up with their targets. Reveal the current street stance and where the consensus sees TSE:4568 heading in the consensus price target analysis for Daiichi Sankyo Company.

Daiichi Sankyo Bears See Margins, Controls And Concentration Risks Confirmed

The bearish view on Daiichi Sankyo says the oncology story is too concentrated, margins are vulnerable and heavy spending may not translate into proportionate earnings. Q1 gives those concerns some backing. Revenue rose 21.1% to ¥574.7b, yet core operating profit only grew 6.2% and profit attributable to owners declined ¥16.9b. That gap shows limited operating leverage so far, even with Enhertu and Datroway ramping.

Bears also worry that high R&D and ADC manufacturing costs, plus profit sharing with partners, could hold margins back. Higher cost of sales, SG&A and R&D, with around ¥32.2b of extra FX driven expenses and some ADC inventory valuation losses, point in that direction. Finally, the FY2025 accounts payable error, even if labeled an isolated processing issue, keeps the internal controls and execution risk argument alive rather than closing it off.

After the accounting issue and rising ADC costs, are these just surface-level problems or early signs of deeper fragility? Review the risk analysis for Daiichi Sankyo Company which shows 1 important warning sign

Take Control Of Your Next Move

If Daiichi Sankyo Company's mix of strong oncology revenue and margin questions has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch how future quarters reshape the thesis. Once you are invested, keep your emotions in check and focus on what matters most with the Portfolio Command Center that brings critical events and fundamental updates together in one view. Round out your process by comparing your thinking with thousands of other investors through the Community and see what risks or catalysts others are highlighting. This way you can spot potential turning points early, tighten your decision making and stay a step ahead of the market.

Seeking Alternatives Beyond Daiichi Sankyo

Fresh ideas do not stay quiet for long. Some stocks are building quiet momentum and could be flying before most even notice. Scan these under the radar for now and get in early.

• Spot companies with resilient cash flows and solid footing before they are widely talked about by running your filters through the list of solid balance sheet and fundamentals stocks (39 results).
• Catch real earnings power in AI early by focusing on profitable operators instead of hype heavy stories using the curated 70 profitable AI stocks that aren't just burning cash.
• Follow capital flowing into critical metals that underpin global electrification trends by checking which producers stand out in the 8 top copper producer stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com